JAMA Network
About The Study: Maternal respiratory syncytial virus prefusion F (RSVpreF) vaccination was associated with protection against RSV-associated acute respiratory illness and lower respiratory tract disease hospitalization among infants 90 days or younger. These findings provide early clinical evidence supporting the effectiveness of maternal RSVpreF vaccination in preventing RSV-associated hospitalization in infants.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
